Tirzepatide

Overview

Tirzepatide (development code LY3298176; brand names Mounjaro and Zepbound) is a once-weekly injectable peptide developed by Eli Lilly. Unlike many peptides documented on this site, tirzepatide is a fully approved prescription medicine in both the United States and the European Union. It is the first drug in its class: a dual agonist that activates two distinct gut-hormone (incretin) receptors at once: the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 (glucagon-like peptide-1) receptor.

The same molecule is sold under two brand names for different indications:

• Mounjaro, approved for the treatment of type 2 diabetes mellitus (initial U.S. approval May 2022; EU authorisation 15 September 2022).
• Zepbound, approved for chronic weight management in adults with obesity or overweight (U.S. approval November 8, 2023) and, subsequently, for moderate-to-severe obstructive sleep apnea in adults with obesity (U.S. approval December 2024).

Tirzepatide belongs to the same broad therapeutic area as the GLP-1 receptor agonist semaglutide (Ozempic/Wegovy) and the investigational triple agonist retatrutide, but its defining feature is the combination of GIP and GLP-1 activity in a single molecule.

Chemistry and structure

Tirzepatide is a synthetic 39-amino-acid peptide whose backbone is based on the native GIP sequence but engineered to also bind and activate the GLP-1 receptor. To extend its duration of action, a C20 fatty-diacid (eicosanedioic acid) moiety is attached, via a glutamic acid spacer and two short linker units, to the side chain of a lysine residue. This lipid "tail" promotes binding to circulating albumin, which slows clearance and gives the molecule a long half-life suitable for once-weekly dosing.

The combination of a peptide backbone optimized across both receptors and an albumin-binding lipid chain is what allows a single weekly injection to produce sustained receptor engagement.

Mechanism of action (dual agonism)

GIP and GLP-1 are incretin hormones released by the gut after eating. Both enhance glucose-dependent insulin secretion from the pancreas, meaning they stimulate insulin mainly when blood glucose is elevated, a property that limits hypoglycemia risk compared with insulin or sulfonylureas. GLP-1 additionally slows gastric emptying, acts on appetite centers in the brain to reduce food intake, and suppresses inappropriate glucagon secretion.

Tirzepatide is unusual because it engages both receptor systems:

• GLP-1 receptor agonism drives appetite reduction, slowed gastric emptying, glucose-dependent insulin release, and glucagon suppression.
• GIP receptor agonism contributes additional effects on insulin secretion and insulin sensitivity, lipid handling, and possibly central appetite regulation.

Tirzepatide is not a "balanced" 1:1 agonist. Pharmacology studies describe it as an imbalanced and biased dual agonist: its activity is weighted toward the GIP receptor and shows distinct signaling characteristics at the GLP-1 receptor relative to native GLP-1. The precise contribution of each receptor to the clinical effects in humans is still an area of active research. The net clinical result is improved glycemic control and substantial reductions in body weight.

Clinical evidence

Tirzepatide was studied in two large phase 3 programs: SURPASS (type 2 diabetes) and SURMOUNT (obesity / weight management). These trials were funded by the manufacturer, Eli Lilly.

SURPASS (type 2 diabetes)

Across SURPASS-1 through SURPASS-5, tirzepatide at 5, 10, and 15 mg weekly produced HbA1c reductions of roughly 1.9 to 2.6 percentage points and meaningful weight loss, generally exceeding active comparators.

• SURPASS-1 (Rosenstock et al., Lancet 2021): As monotherapy versus placebo in 478 adults over 40 weeks, all tirzepatide doses significantly lowered HbA1c and body weight, without increased hypoglycemia.
• SURPASS-2 (Frías et al., NEJM 2021): A head-to-head comparison against the GLP-1 agonist semaglutide 1 mg in 1,879 adults on metformin. Over 40 weeks, all three tirzepatide doses were noninferior and superior to semaglutide for HbA1c reduction, with greater weight loss as well. Gastrointestinal side effects were broadly comparable between the two drugs.

SURMOUNT (obesity / weight management)

• SURMOUNT-1 (Jastreboff et al., NEJM 2022): In 2,539 adults with obesity or overweight (without diabetes), 72 weeks of tirzepatide produced mean weight reductions of about 16.0% (5 mg), 21.4% (10 mg), and 22.5% (15 mg), versus 2.4% with placebo. The reduction was weighted toward fat mass rather than lean mass, although some lean-mass loss occurred (see Safety).
• SURMOUNT-OSA (Malhotra et al., NEJM 2024): In adults with obesity and moderate-to-severe obstructive sleep apnea, tirzepatide significantly reduced the apnea-hypopnea index and improved related cardiometabolic measures, supporting the December 2024 Zepbound approval for OSA.

Cardiovascular and heart-failure outcomes

• SURPASS-CVOT (Nicholls et al., NEJM 2025): A large (~13,000-patient) event-driven trial in adults with type 2 diabetes and established atherosclerotic cardiovascular disease compared tirzepatide head-to-head against the GLP-1 agonist dulaglutide (an active comparator with proven cardiovascular benefit). Over a median follow-up of about 4 years, tirzepatide was noninferior to dulaglutide for the primary three-point MACE outcome (cardiovascular death, myocardial infarction, or stroke), but did not reach statistical superiority for that endpoint; it showed greater reductions in HbA1c, body weight, blood pressure, and lipids. This was the first dedicated cardiovascular outcomes trial for tirzepatide.
• SUMMIT (HFpEF): In adults with obesity and heart failure with preserved ejection fraction, tirzepatide reduced a composite of worsening heart-failure events and cardiovascular death versus placebo and improved physical function. As of mid-2026 this is not yet a separately approved indication; the data have been submitted to regulators.

A consistent and important finding across the weight-management literature is that the benefit is dependent on continued treatment: when tirzepatide is stopped, appetite returns and a substantial portion of lost weight tends to be regained.

Safety and risks

Tirzepatide has a defined and serious safety profile. The points below reflect the U.S. prescribing information and trial data; they are presented honestly and are not exhaustive.

Gastrointestinal effects (most common). The dominant side effects are gastrointestinal and are usually mild-to-moderate and dose-related. In placebo-controlled trials, the most common adverse reactions (≥5%) included nausea (about 12–18% across doses), diarrhea (about 12–17%), decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain. These are most prominent during dose escalation. Severe GI reactions can cause dehydration, which has been associated with acute kidney injury.

Acute pancreatitis. Pancreatitis has been reported with incretin-based drugs; the label advises stopping tirzepatide if pancreatitis is suspected. This remains a recognized signal rather than a firmly quantified risk, and some analyses have not found a clear association; the topic is still being monitored (for example, post-marketing pharmacovigilance reviews of GLP-1/GIP agents).

Gallbladder disease. Cholelithiasis (gallstones) and acute gallbladder disease have been reported, consistent with the gallbladder effects seen with rapid weight loss and GLP-1-class drugs.

Hypoglycemia. Tirzepatide alone rarely causes low blood sugar, but the risk rises when it is combined with insulin or insulin secretagogues (sulfonylureas); dose adjustment of those medications may be needed.

Other warnings. The label notes potential serious hypersensitivity reactions (including anaphylaxis and angioedema), diabetic retinopathy monitoring in people with a history of it, delayed gastric emptying that may affect oral medications and raises concern about pulmonary aspiration under anesthesia/deep sedation, and caution in severe gastrointestinal disease such as severe gastroparesis.

Muscle / lean-mass loss. As with other potent weight-loss therapies, a meaningful share of the weight lost can include lean (muscle) mass, not only fat. In SURMOUNT-1, fat-mass loss exceeded lean-mass loss (roughly a 3:1 ratio), but lean-mass loss still occurred. This has prompted clinical interest in resistance exercise and adequate protein intake during treatment, and in strategies to preserve muscle.

Discontinuation and weight regain. Because the metabolic and appetite-suppressing effects depend on ongoing dosing, stopping the drug is associated with return of appetite and weight regain. Approved weight-management use is therefore framed as a long-term therapy, not a short course.

Pregnancy. Weight loss is not recommended during pregnancy; the manufacturer advises against use in pregnancy for the weight-management indication and there is a pregnancy exposure registry. People who could become pregnant should discuss contraception and the potential reduced effectiveness of oral contraceptives around dose changes with their clinician.

Regulatory status

United States (FDA — approved):

• May 2022: Approval of Mounjaro for type 2 diabetes.
• November 8, 2023: Approval of Zepbound for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity.
• December 2024: Approval of Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first drug approved for this OSA indication.
• 2025–2026: The dedicated cardiovascular outcomes trial SURPASS-CVOT (NEJM, December 2025) reported that tirzepatide was noninferior — but not superior — to dulaglutide for major adverse cardiovascular events in type 2 diabetes. Data from the SUMMIT trial in heart failure with preserved ejection fraction (HFpEF) and obesity have been submitted to regulators; as of mid-2026 HFpEF and a standalone cardiovascular risk-reduction claim are not yet separately approved indications.

European Union (EMA — approved):

• 15 September 2022: Mounjaro (tirzepatide) received EU marketing authorisation (marketing authorisation holder Eli Lilly Nederland B.V.) for type 2 diabetes and, per the label, for weight management in adults with obesity or overweight with a weight-related comorbidity.

Tirzepatide is a prescription-only medicine in both jurisdictions. It is not an over-the-counter product, a supplement, or a "research chemical," despite being marketed as such by some unregulated vendors.

How it compares

Tirzepatide is one of several incretin-based metabolic drugs. The table below is a neutral, factual comparison; it is not a ranking or a recommendation, and approval status differs sharply between agents.

In the head-to-head SURPASS-2 trial, tirzepatide produced greater HbA1c and weight reductions than semaglutide 1 mg in people with type 2 diabetes. Retatrutide adds a third receptor (glucagon) and showed large weight loss in a phase 2 trial, but it is not approved by any regulator and remains investigational. Comparisons across separate trials should be read cautiously because populations, doses, and durations differ.

Common misconceptions

---

This article is provided for educational purposes only and is not medical advice. Tirzepatide (Mounjaro / Zepbound) is a prescription medication that should be used only under the supervision of a qualified healthcare professional, who can assess contraindications, drug interactions, and the monitoring required for safe use. Nothing here should be interpreted as encouragement to obtain or use tirzepatide outside of an approved, supervised clinical context.

Community claims & recent evidence

These points address claims circulating in the peptide community — including popular video "masterclasses" that pit tirzepatide against retatrutide — checked against primary sources. A knowledgeable creator is not peer review; each statement was treated as a claim to verify.

Verified additions

• Tirzepatide can resolve steatohepatitis (MASH/NASH) — but this is phase 2, not an approved use. In the 52-week randomized SYNERGY-NASH trial of patients with biopsy-confirmed MASH and F2–F3 fibrosis, MASH resolution without worsening of fibrosis occurred in 51.8%, 62.8%, and 73.3% at 5, 10, and 15 mg versus 13.2% with placebo, and fibrosis improved by ≥1 stage in roughly half of treated patients. [Human] (Loomba R, Hartman ML, et al., New England Journal of Medicine 2024). This is the real evidence behind community talk that "these drugs fix fatty liver": for tirzepatide it is genuine, biopsy-confirmed data — but still investigational for liver disease and not an approved indication.
• GIP's role in fat tissue is genuinely unresolved, not settled. GIP-receptor activation has been shown to increase whole-body lipid oxidation, adipose blood flow, and insulin sensitivity, and — paradoxically — both GIPR agonism and antagonism can lower body weight; its net effect in adipose is context-dependent (fed vs fasted, lean vs obese). [Human]/[Animal] (Samms RJ & Sloop KW, Diabetes 2025; Kagdi, Lyons & Beaudry, Journal of Endocrinology 2024).
• No completed head-to-head trial of tirzepatide vs retatrutide exists yet. Eli Lilly's direct randomized comparison (ClinicalTrials.gov NCT06662383) is ongoing, with results expected around late 2026. Every current "one beats the other" figure is a cross-trial comparison across different populations, doses, and durations, and should be read cautiously. [Human] (ClinicalTrials.gov NCT06662383).

Claims that don't hold up

• Claim: "A 2023 study in Cell directly compared the two and found retatrutide gave 22% greater weight loss and 30% greater fat-free-mass preservation than tirzepatide." No such head-to-head trial exists — the only direct randomized comparison (NCT06662383) is still running. Across separate trials the fat-to-lean loss ratio is comparable (roughly 3:1) for tirzepatide (SURMOUNT-1) and retatrutide (Jastreboff AM, et al., NEJM 2023, ~74% of lost weight was fat by DEXA), so the specific muscle-sparing advantage is unsupported and the cited paper does not resolve to a real source. [Human]
• Claim: "An Endo 2024 presentation showed ~40% weight loss on retatrutide vs ~18% on tirzepatide in metabolically normalized patients." This dataset does not resolve to any real abstract or publication; it cannot be verified against a primary source and is dropped as an invented citation. [Hypothesis]
• Claim: "Tirzepatide is purely a 'storage-prevention' drug because GIP hammers the off-switch, suppressing adipogenesis and lipogenic genes." This overstates contested science. The longstanding and still-dominant view is that GIP is anabolic in adipose tissue (it promotes fat deposition in the fed, insulin-replete state); the receptor's net effect is context-dependent and remains an active controversy. Tirzepatide's weight effect is also not "just blocking storage" — GLP-1-driven appetite suppression, delayed gastric emptying, and improved insulin sensitivity all contribute. [Human]/[Animal] (Campbell JE, et al., Diabetes 2025; Samms RJ & Sloop KW, Diabetes 2025).